Ministry of Health, Welfare and Sport

**Office of Medicinal Cannabis**

# Release certificate

| | | | |
|---|---|---|---|
| Product | **Cannabis flos, variety Bedrolite (hemp flowers)**<br>**CBD-dominant type**<br>to be prescribed to patients as a medicinal product | | |
| Strength | tetrahydrocannabinol: ≤ 1.0% | cannabidiol: ≥ 5.0% | |
| Dosage form | flowers, granulated | | |
| Package size and type | 5 grams in container, 400 grams in bags | | |
| Testing method | European Pharmacopoeia (Ph. Eur.) 07/2024:3028 | | |
| Batch | **25L15FR26A14** | | |
| Order numbers | containers 387540<br>bags 387539 | | |
| Expiry date | 30 Nov. 2026 | | |
| Grower/drier | Bedrocan Nederland B.V.<br>P.O. Box 2009<br>NL- 9640 CA Veendam | harvest date:<br>15 Dec. 2025 | |
| Gamma irradiation | Synergy Health Ede B.V.<br>Soevereinstraat 2<br>NL-4879 NN Etten-Leur | date:<br>14 Jan. 2026 | dose:<br>≥ 10,0 kGy |
| Packager | Fagron Nederland B.V.<br>Venkelbaan 101<br>NL-2908 KE Capelle a/d IJssel | date:<br>05 – 06 Feb. 2026 | |
| Laboratory | Laboratorium Ofichem B.V.<br>Heembadweg 5<br>NL-9561 CZ Ter Apel | 1. General analysis<br>Analysis number:<br>Report date: | 55488<br>30 Jan. 2026 |
| | | 2. Microbiology of end product in container<br>Analysis number:<br>Report date: | 55950<br>23 Feb. 2026 |

P.O. Box 16114
NL-2500 BC THE HAGUE
The Netherlands
Telephone +31 70 340 5113
Telefax +31 70 340 7426

Address:
Hoftoren
Rijnstraat 50
NL-2515 XP THE HAGUE
The Netherlands

All correspondence addressed to the postal address quoting date and reference of this letter.

Internet address:
www.minvws.nl
www.cannabisbureau.nl
e-mail:
info@cannabisbureau.nl

**Results of analysis**

| | Method | Specification | Result |
|---|---|---|---|
| Appearance | Visual | Dried, fragmented, fully developed female inflorescence of Cannabis sativa L.<br>Stalks are no longer than 2.0 cm and only 20% of the stalks are between 1.5 and 2.0 cm. | Complies |
| Identification | | | |
| Macroscopic botanical characters | Monograph | Conform Identification A. | Complies |
| Microscopic botanical characters | Monograph | Conform Identification B. | Complies |
| High-performance thin-layer chromatography | Monograph | Comparable with reference and test solutions CBD-dominant type.<br>Conform Identification C. | Complies |
| Loss on drying | Monograph | ≤ 12.0% | 7.9 % |
| | | Maximum 2% | 1 % |
| Foreign material | Monograph | It does not contain any seeds or other foreign elements and the whole herbal drug does not contain any leaves more than 1.0 cm in length. | Complies |
| Aflatoxins | | | |
| Aflatoxin $B_1$ | Ph. Eur. (current ed.) 2.8.18 | ≤ 2 µg/kg | < 2 µg/kg |
| Sum of aflatoxins $B_1$, $B_2$, $G_1$ and $G_2$ | | ≤ 4 µg/kg | < 4 µg/kg |
| Pesticides | Ph. Eur. (current ed.) 2.8.13 | ≤ Limits Ph. Eur. 2.8.13* | Complies |
| Heavy metals | | | |
| Arsenic | Monograph | ≤ 0.2 ppm | < 0.1 ppm |
| Cadmium | | ≤ 0.3 ppm | < 0.2 ppm |
| Lead | | ≤ 0.5 ppm | < 0.3 ppm |
| Mercury | | ≤ 0.1 ppm | < 0.1 ppm |
| Assay (HPLC) | | | |
| Tetrahydrocannabinol (THC, total equivalent) | Monograph | ≤ 1.0% | 0. 3 % |
| Cannabidiol (CBD, total equivalent) | | ≥ 5.0% | 7.6 % |
| Related substances (HPLC) | | | |

Ministry of Health, Welfare and Sport

**Office of Medicinal Cannabis**


Our reference
25L15FR26A14

**Results of analysis**

| | Method | Specification | Result |
|---|---|---|---|
| Cannabinol (CBN, total equivalent) | Monograph | ≤ 1.0% | < 0.1 % |
| Microbial contamination | | | |
| Total aerobic microbial count (TAMC) | Ph. Eur. (current ed.) 2.6.12, 2.6.13 | ≤$10^2$ cfu/gram | < $10^2$ cfu/gram |
| Total combined yeasts/moulds count (TYMC) | | ≤$10^1$ cfu/gram | < $10^1$ cfu/gram |
| S. aureus, P. aeruginosa, bile-tolerant gram-negative bacteria | | Absent (1 gram) | Complies |

**The following pesticides are not analysed: dithiocarbamates (expressed as CS2), methoxychlor, paraoxon-methyl and tetradifon. The limit of detection is increased for fenpropathrin to 0.1 mg/kg and azinphos-ethyl to 1 mg/kg.*

I hereby certify that the above information is authentic and accurate. This batch of product has been cultivated, manufactured, gamma irradiated, packaged and tested in full compliance with the GACP and GMP requirements and with the specifications as stated in this document.

The Hague, the Netherlands, 26 February 2026

K. Amponsah / S. Vos- de Schipper
QA, Office of Medicinal Cannabis